Highest-materiality recent filing
Lite Strategy reports $0.7M yield from LTC covered calls, repurchases 1.6M shares
Generated $0.7M net proceeds from covered call program on LTC holdings since Oct 2025.
Lite Strategy Q2 results: $600k from covered call program, launches $25M buyback
Generated ~$600,000 in gross premiums from covered call options on LTC holdings.
Stockholders approve 2026 equity plan and elect directors at annual meeting
Stockholders approved the 2026 Omnibus Equity Compensation Plan, authorizing up to 2,000,000 new shares for equity grants.
Lite Strategy finalizes CEO Justin File employment agreement with $575K base salary
Agreement dated Dec 23, 2025, effective Nov 14; replaces prior agreement.
Lite Strategy dismisses Deloitte, appoints CBIZ CPAs as auditor for FY2026
Audit committee dismissed Deloitte & Touche LLP and engaged CBIZ CPAs P.C. as independent auditor effective December 2, 2025.
Lite Strategy corrects CEO option grant; grants 455K replacement options at $2.02
Corrects original 8-K: CEO Justin File received 180,000 options, not 635,000 as previously reported.
Lite Strategy appoints Justin J. File as permanent CEO and grants 635K options
Justin J. File, previously Acting CEO and CFO/Secretary, named permanent CEO effective Nov 14, 2025.
Lite Strategy authorizes $25M share repurchase; director Reynolds resigns
Board authorized $25M share repurchase program, effective immediately, through open market or negotiated transactions.
Investor exercises 1.595M pre-funded warrants in cashless exercise for 1.594M shares
On Sept 10, 2025, an investor exercised 1,595,000 pre-funded warrants issued at $3.4199 each in a cashless exercise.
MEI Pharma rebrands as Lite Strategy, Inc., adopts digital asset treasury with LTC
Company changes name to Lite Strategy, Inc.; NASDAQ ticker changes from MEIP to LITS effective Sep 11, 2025.
MEI Pharma enters Master Loan Agreement with BitGo Prime for digital asset and USD borrowings
Master Loan Agreement with BitGo Prime allows MEI to borrow digital assets or USD, secured by collateral.
Director Steven Wood resigns; Joshua Riezman elected to MEI Pharma board
Steven D. Wood resigned from the board effective August 5, 2025; no disagreement cited.
Acquired 929,548 LTC tokens at avg price $107.58; LTC treasury valued at ~$110.4M as of Aug 4, 2025.
MEI Pharma reports exercise of pre-funded warrants for 2.08M shares of common stock
Investor exercised Pre-Funded Warrants to purchase 2,084,509 shares of common stock on July 24, 2025.
MEI Pharma Raises $100M in PIPE to Launch Litecoin Treasury Strategy; Charlie Lee Appointed to Board
Gross proceeds of ~$100M from sale of 29.2M shares/pre-funded warrants at $3.42 per share.
MEI Pharma reports $20.5M cash; strategic alternatives review ongoing
Cash and cash equivalents $20.5M as of March 31, 2025, with no outstanding debt.
Base salary $550,000 (eff Aug 1, 2024); target bonus 50% of base salary for FY2025.
MEI Pharma reports $23.7M cash, no debt, continues strategic alternatives review
Cash and cash equivalents $23.7M as of Dec 31, 2024; no outstanding debt.
MEI Pharma annual meeting results: directors elected, say-on-pay approved, auditors ratified
Frederick W. Driscoll and Nicholas R. Glover elected as directors with 2,360,948 and 2,722,093 votes for, respectively.
MEI Pharma sets 2025 annual meeting for Jan 30, 2025; record date Dec 9, 2024
2025 Annual Meeting to be held on January 30, 2025.
MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review
Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.
MEI Pharma sells rights to ME-344 to Aardvark Therapeutics for up to $62.5M milestones
Closed on Oct 22, 2024: sold ME-344 assets (IP, contracts, technology) to Aardvark Therapeutics for $0.5M upfront plus $55K reimbursement.
MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives
Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.
CEO and CMO depart; MEI Pharma evaluates wind-down; CFO becomes Acting CEO
CEO David M. Urso and CMO Richard G. Ghalie depart effective Aug 1, 2024; eligible for severance (12 mo salary, COBRA, prorated bonus, accelerated vesting).
MEI Pharma halts voruciclib clinical development, begins strategic alternatives review
Board unanimously decided to evaluate strategic alternatives including potential transactions or orderly wind-down.
MEI Pharma halts voruciclib, cuts workforce, CEO/CMO depart, evaluates wind-down
Board unanimously begins evaluation of strategic alternatives including transactions or orderly wind-down.
MEI Pharma terminates office lease; pays $11.1M fee, saves $2.6M/year
Lease at 11455 El Camino Real, San Diego terminated as of Sept 30, 2024 (original expiry Nov 30, 2029).
MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium
CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.
MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program
Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.
MEI Pharma signs $25M ATM equity facility, initially capped at $10.3M due to float limit
Entered into Capital on Demand Sales Agreement with JonesTrading to sell up to $25M of common stock in ATM offerings.
Cash, cash equivalents and short-term investments of $59.5M at Dec 31, 2023, with no outstanding debt.
MEI Pharma enters new CMO employment agreement; $503K salary, 40% bonus
Dr. Richard Ghalie continues as CMO under new agreement effective Jan 16, 2024; base salary $503,165.28, target bonus 40% of base.
MEI Pharma dismisses BDO as auditor, appoints Deloitte effective Dec 26, 2023
Dismissed BDO USA, P.C. as independent auditor on Dec 19, 2023; no adverse opinions or disagreements in recent fiscal years.
MEI Pharma adopts Sixth Amended and Restated Bylaws effective December 18, 2023
Board designated at eight directors; amendments conform to revised DGCL.
MEI Pharma stockholders elect directors and approve say-on-pay at 2023 annual meeting
Shareholders elected James Flynn, Taheer Datoo, and Steven Wood to three-year board terms.
Voruciclib monotherapy up to 200 mg on intermittent schedule well-tolerated; no DLTs. Common AEs: diarrhea, nausea, anemia, fatigue.
MEI Pharma Q1 net income $56.4M on deferred revenue; clinical trials on track
Net income $56.4M ($8.46 EPS) vs prior-year net loss $16.6M; revenue $65.3M from Kyowa Kirin termination.
Immediate dividend of $1.75 per share paid to all stockholders; potential additional $9.33M return contingent on ME-344 trial results or Board decision.
MEI Pharma adopts poison pill after Anson/Cable Car accumulate ~19.9% stake
Rights plan triggers at 20% ownership; expires September 30, 2024.
MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed
Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.
MEI Pharma promotes Justin File to CFO; Brian Drazba departs without cause
Justin J. File appointed CFO and Corporate Secretary effective August 1, 2023.
MEI Pharma terminates merger with Infinity after stockholder vote fails
Stockholders voted against merger: 47.86% for, 51.44% against; turnout 59.70% of outstanding shares.
Mutually terminated License, Development and Commercialization Agreement with Kyowa Kirin for ME-401 effective July 14, 2023.
MEI Pharma rejects activist consent solicitation to remove board without cause under Delaware law
Anson Advisors and Cable Car Capital launched consent solicitation on July 17, 2023 to remove all directors without cause and repeal recent bylaw amendments.
MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting
MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.
MEI Pharma postpones special meeting on Infinity merger to July 23, 2023
Special meeting postponed from original date to July 23, 2023 at 10:00 a.m. ET; may be further adjourned.
Glass Lewis joins ISS in recommending MEI Pharma shareholders vote FOR Infinity merger
Both ISS and Glass Lewis recommend shareholders vote FOR the Infinity merger.
ISS recommends MEI Pharma shareholders vote FOR merger with Infinity Pharma
Independent proxy advisory ISS recommends voting FOR the Infinity merger at July 14 special meeting.
MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting
Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.
MEI Pharma Board Rejects Anson/Cable Car Unsolicited Bid, Reaffirms Infinity Merger
Board unanimously rejects unsolicited, non-binding proposal from Anson Advisors and Cable Car Capital as undervaluing the Company.
David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, the Company’s President and Chief Executive Officer, and Richard G. Ghalie, M.D., its Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024.
The Board has appointed Frederick W. Driscoll as Chairperson of the Company.
The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024.
Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately.
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Mr. Steven Wood, as mutually agreed upon by the Company and Anson Funds and Cable Car, has been appointed to the Board as an additional MEI stockholder representative designated by the Board.
the Company has appointed two directors designated by Anson Funds and Cable Car: Mr. James Flynn and Mr. Taheer Datoo.
Daniel P. Gold, Ph.D., Tamar D. Howson and Sujay R. Kango have tendered their resignations as directors of the Board
Max materiality 0.95 · Median 0.60 · Most common event other_material